Xefecta (400mg/250ml) 1 Injection

This medicine is indicated in Acute exacerbation of chronic bronchitis, acute bacterial sinusitis, community acquired pneumonia (CAP) when other antibiotics cannot be used or have failed. Mild to moderate pelvic inflammatory disease, without associated tubo-ovarian or pelvic abscess, in combination with another antibiotic (unless moxifloxacin-resistant Neisseria gonorrhoea can be excluded). Completion of therapy in CAP and complicated skin and skin structure inlections that have responded to IV moxifioxacin

Abdominal pain, headache, dizziness, GI upset, QT prolongation in patients with hypokalaemia, abnormal LFTs. Superinfections, pseudomembranous colitis

Risk of seizures: discontinue if occur. Seek specialist ophthalmological advice if any effects on eyes. Risk of tendon inflammation/rupture; advise patients (especially elderly to report limb pain or inflammation. Proarrhythmic conditions including acute MI and QT prolongation discontinue immediately with signs of arrhythmia and perform ECG. Risk of pseudomembranous colitis; consider if patient has persistent diarrhoea.Avoid excess UV exposure. Hypersensitivity reactions may progress to life-threatening shock; discontinue and initiate suitable treatment. Risk of neuropathy; advise patients to report relevant symptoms. Risk of fulminant hepatitis; monitor liver function and advise patients to report signs of hepatic diseaseAvoid excess UV exposure. Hypersensitivity reactions may progress to life-threatening shock; discontinue and initiate suitable treatment. Risk of neuropathy; advise patients to report relevant symptoms. Risk of fulminant hepatitis; monitor liver function and advise patients to report signs of hepatic disease